<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/>
  <meta name="type" content="article"/>
  <meta name="category" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/01/31/2020.01.30.927574.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.01.30.927574v1"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Nucleotide Analogues as Inhibitors of Viral Polymerases"/>
  <meta name="DC.Identifier" content="10.1101/2020.01.30.927574"/>
  <meta name="DC.Date" content="2020-01-31"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="© 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3’-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators."/>
  <meta name="DC.Contributor" content="Jingyue Ju"/>
  <meta name="DC.Contributor" content="Shiv Kumar"/>
  <meta name="DC.Contributor" content="Xiaoxu Li"/>
  <meta name="DC.Contributor" content="Steffen Jockusch"/>
  <meta name="DC.Contributor" content="James J. Russo"/>
  <meta name="article:published_time" content="2020-01-31"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Nucleotide Analogues as Inhibitors of Viral Polymerases"/>
  <meta name="citation_abstract" lang="en" content="&lt;;h3&gt;;Summary&lt;;/h3&gt;; &lt;;p&gt;;Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3’-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.01.30.927574v1"/>
  <meta name="citation_id" content="2020.01.30.927574v1"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.01.30.927574v1"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.01.30.927574v1.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.01.30.927574v1.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.01.30.927574"/>
  <meta name="citation_num_pages" content="8"/>
  <meta name="citation_article_type" content="Article"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.01.30.927574"/>
  <meta name="citation_author" content="Jingyue Ju"/>
  <meta name="citation_author_institution" content="Center for Genome Technology and Biomolecular Engineering, Columbia University"/>
  <meta name="citation_author_institution" content="Departments of Chemical Engineering, Columbia University"/>
  <meta name="citation_author_institution" content="Departments of Pharmacology, Columbia University"/>
  <meta name="citation_author_email" content="dj222@columbia.edu"/>
  <meta name="citation_author" content="Shiv Kumar"/>
  <meta name="citation_author_institution" content="Center for Genome Technology and Biomolecular Engineering, Columbia University"/>
  <meta name="citation_author_institution" content="Departments of Chemical Engineering, Columbia University"/>
  <meta name="citation_author" content="Xiaoxu Li"/>
  <meta name="citation_author_institution" content="Center for Genome Technology and Biomolecular Engineering, Columbia University"/>
  <meta name="citation_author_institution" content="Departments of Chemical Engineering, Columbia University"/>
  <meta name="citation_author" content="Steffen Jockusch"/>
  <meta name="citation_author_institution" content="Center for Genome Technology and Biomolecular Engineering, Columbia University"/>
  <meta name="citation_author_institution" content="Departments of Chemistry, Columbia University"/>
  <meta name="citation_author" content="James J. Russo"/>
  <meta name="citation_author_institution" content="Center for Genome Technology and Biomolecular Engineering, Columbia University"/>
  <meta name="citation_author_institution" content="Departments of Chemical Engineering, Columbia University"/>
  <meta name="citation_reference" content="Alanazi AS, James E, Mehellou Y (2019) The ProTide prodrug technology: where next? ACS Med Chem Lett 10:2–5."/>
  <meta name="citation_reference" content="Guo J, Xu N, Li Z, Zhang S, Wu J, Kim DH, Sano Marma M, Meng Q, Cao H, Li X, Shi S, Yu L, Kalachikov S, Russo JJ, Turro NJ, Ju J (2008) Four-color DNA sequencing with 3’-O-modified nucleotide reversible terminators and chemically cleavable fluorescent dideoxynucleotides. Proc Natl Acad Sci USA 105:9145–9150."/>
  <meta name="citation_reference" content="Ju J, Kim DH, Bi L, Meng Q, Bai X, Li Z, Li X, Marma MS, Shi S, Wu J, Edwards JR, Romu A, Turro NJ (2006) Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators. Proc Natl Acad Sci USA 103:19635–19640."/>
  <meta name="citation_reference" content="Ju J, Li Z, Edwards JR and Itagaki Y (2003) Massive Parallel Method for Decoding DNA and RNA. United States Patent 6,664,079."/>
  <meta name="citation_reference" content="Ross BS, Reddy PG, Zhang H-R, Rachakonda S, Sofia MJ (2011) Synthesis of diastereomerically pure nucleotide phosphoramidates. J Org Chem 76:8311–8319."/>
  <meta name="citation_reference" content="Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang H-R, Bansal S, Espiritu C, Keilman M, Lam AM, Micolochick Steuer HM, Niu C, Otto MJ, Furman PA (2010) Discovery of a β-D-2’-Deoxy-2’-α-fluoro-2’-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53:7202–7218."/>
  <meta name="citation_reference" content="Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402–405."/>
  <meta name="citation_reference" content="Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, for the China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Eng J Med. DOI: 10.1056/NEJMoa2001017."/>
  <meta name="citation_reference" content="Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y (2016) Coronaviruses – drug discovery and therapeutic options. Nat Rev J Drug Discovery 15:327–347."/>
  <meta name="twitter:title" content="Nucleotide Analogues as Inhibitors of Viral Polymerases"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3’-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators."/>
  <meta name="og-title" property="og:title" content="Nucleotide Analogues as Inhibitors of Viral Polymerases"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.01.30.927574v1"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3’-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators."/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-01-31"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Nucleotide Analogues as Inhibitors of Viral Polymerases | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1129071 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-type-article hw-article-category-new-results"> 
  <div class="article fulltext-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2 class="">Summary</h2>
    <p id="p-2">Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3’-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.</p>
   </div>
   <p id="p-3">The recent appearance of clusters of a new coronaviral infection in Wuhan, China has made headlines, as more and more people have become infected in China and in a number of other countries. Already more than 100 deaths have been ascribed to this virus, and there are fears of additional outbreaks. The virus has been isolated from the lower respiratory tracts of patients with pneumonia, sequenced and visualized by electron microscopy (
    <a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">Zhu et al 2020</a>). The virus, which has received the placeholder name 2019-nCoV, turns out to be a new member of the subgenus sarbecovirus, in the Orthocoronavirinae subfamily, but is distinct from MERS CoV and SARS CoV (
    <a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">Zhu et al 2020</a>). The coronaviruses are positive-sense, single strand RNA viruses, and thus share properties with other single-stranded RNA viruses such as hepatitis C virus, West Nile virus, Marburg virus, HIV virus, Ebola virus, dengue virus, and rhinoviruses.
   </p>
   <p id="p-4">The coronavirus life cycle is depicted in 
    <a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1</a>, which is taken from a review by 
    <a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">Zumla et al (2016)</a>. Briefly, the virus enters the cell by endocytosis, is uncoated and ORF1a and ORF1b of the + strand RNA is translated to produce nonstructural proteins, including a cysteine protease, a serine protease, helicase and RNA-dependent RNA polymerase (RdRp). The proteases cleave the precursor forms of the helicase and RdRp to form mature, functional molecules. A replication-transcription complex is then formed, which is responsible for making more copies of the RNA genome via a negative-sense intermediate, as well as the structural and other proteins encoded by the viral genome. The viral RNA is packaged into viral coats, attaches to the cell surface, after which exocytosis results in release of viral particles for subsequent infectious cycles. Potential inhibitors have been designed to attack nearly every stage of this process, as indicated in 
    <a id="xref-fig-1-2" class="xref-fig" href="#F1">Fig. 1</a> (
    <a id="xref-ref-9-2" class="xref-bibr" href="#ref-9">Zumla et al 2016</a>). Despite decades of research, no effective drug is currently available to treat such serious coronavirus infections as SARS, MERS, and the symptoms caused by 2019-nCoV.
   </p>
   <div id="F1" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F1.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Virus-based and host-based treatment options targeting the coronavirus replication cycle. From Zumla et al (2016) Nat Rev | Drug Discovery 15:327-347." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;div xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;;&gt;;Virus-based and host-based treatment options targeting the coronavirus replication cycle. &lt;;em&gt;;From Zumla et al (2016) Nat Rev | Drug Discovery 15:327-347.&lt;;/em&gt;;&lt;;/div&gt;;&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 1:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F1.medium.gif" width="325" height="440"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 1:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F1.medium.gif" width="325" height="440"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F1.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 1:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F1.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 1:</span>
     <p id="p-5" class="first-child">Virus-based and host-based treatment options targeting the coronavirus replication cycle. 
      <em>From 
       <a id="xref-ref-9-3" class="xref-bibr" href="#ref-9">Zumla et al (2016)</a> Nat Rev | Drug Discovery 15:327-347.
      </em>
     </p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <p id="p-6">One of the most important druggable targets is the RdRp. Example drugs include Gilead’s sofosbuvir (which is paired with velpatasvir as the FDA-approved drug EPCLUSA), to inhibit the RNA-dependent RNA polymerase of the hepatitis C virus. Sofosbuvir, a pyrimidine nucleotide analogue (
    <a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 2</a>) with a blocked phosphate group enabling it to enter infected eukaryotic cells, is a prodrug, which is converted into its active triphosphate form by cellular enzymes (
    <a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 3</a>). The activated drug binds in the active site of the RdRp, where it is incorporated into RNA, and due to modifications at the 2’ position, inhibits further RNA chain extension and halts RNA replication. It acts as an RNA polymerase inhibitor by competing with natural ribonucleotides.
   </p>
   <div id="F2" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F2.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Structure of Sofosbuvir, a component of the FDA-approved drug EPCLUSA." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;Structure of Sofosbuvir, a component of the FDA-approved drug EPCLUSA.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 2:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F2.medium.gif" width="440" height="342"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 2:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F2.medium.gif" width="440" height="342"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F2.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 2:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F2.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 2:</span>
     <p id="p-7" class="first-child">Structure of Sofosbuvir, a component of the FDA-approved drug EPCLUSA.</p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <div id="F3" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F3.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Conversion of sofosbuvir to active drug in vivo. From https://en.wikipedia.org/wiki/Sofosbuvir." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;div xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;;&gt;;Conversion of sofosbuvir to active drug &lt;;em&gt;;in vivo. From https://en.wikipedia.org/wiki/Sofosbuvir.&lt;;/em&gt;;&lt;;/div&gt;;&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 3:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F3.medium.gif" width="440" height="217"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 3:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F3.medium.gif" width="440" height="217"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F3.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 3:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F3.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 3:</span>
     <p id="p-8" class="first-child">Conversion of sofosbuvir to active drug 
      <em>in vivo. From 
       <a href="https://en.wikipedia.org/wiki/Sofosbuvir">https://en.wikipedia.org/wiki/Sofosbuvir</a>.
      </em>
     </p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <p id="p-9">Based on our insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA for the treatment of hepatitis C will also inhibit coronaviruses, including 2019-nCoV and those responsible for SARS and MERS.</p>
   <p id="p-10">There are many other RNA polymerase inhibitor drugs which are used as antivirals. A related purine nucleotide prodrug, remdesivir (
    <a id="xref-fig-4-1" class="xref-fig" href="#F4">Fig. 4</a>), was developed by Gilead to treat Ebola virus infections, though not very successfully, and is currently being considered for repositioning to treat the 2019-nCoV outbreak (
    <a href="https://www.fiercebiotech.com/biotech/gilead-mulls-repositioning-failed-ebola-drug-china-virus">https://www.fiercebiotech.com/biotech/gilead-mulls-repositioning-failed-ebola-drug-china-virus</a>). In contrast to sofosbuvir, both the 2’- and 3’-OH groups are unmodified, but a cyano group at the 1’ position presumably serves to inhibit the RdRp in the active triphosphate form. Additional information on the ProTide Prodrug technology is described by 
    <a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">Alanazi et al (2019)</a>.
   </p>
   <div id="F4" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F4.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Structure of remdesivir." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;Structure of remdesivir.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 4:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F4.medium.gif" width="440" height="394"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 4:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F4.medium.gif" width="440" height="394"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F4.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 4:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F4.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 4:</span>
     <p id="p-11" class="first-child">Structure of remdesivir.</p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <p id="p-12">A related prodrug analogue developed by BioCryst Pharmaceuticals, BCX4430, also known as galidesivir (
    <a id="xref-fig-5-1" class="xref-fig" href="#F5">Fig. 5</a>), has been shown to inhibit RNA polymerases from a broad spectrum of RNA viruses, notably including the filoviruses (e.g., Ebola, Marburg) in rodents and Marburg virus in macaques (
    <a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">Warren et al 2014</a>). Upon entry into infected cells, BCX4430 is rapidly phosphorylated, and the resulting nucleoside triphosphate serves as an RNA chain terminator.
   </p>
   <div id="F5" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F5.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Structure of BCX4430." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;Structure of BCX4430.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 5:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F5.medium.gif" width="440" height="343"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 5:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F5.medium.gif" width="440" height="343"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F5.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 5:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F5.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 5:</span>
     <p id="p-13" class="first-child">Structure of BCX4430.</p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <p id="p-14">Based on the above background information, we describe here a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3’-blocking groups that we have built into nucleotide analogues that function as reversible terminators for DNA sequencing (
    <a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">Ju et al 2003</a>, 
    <a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">Ju et al 2006</a>, 
    <a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">Guo et al 2008</a>). We reasoned that (1) the phosphate masking groups will allow entry of the compounds into infected cells, (2) the 3’-blocking group on the 3’-OH with either free 2’-OH or modifications at the 2’ position will encourage incorporation of the activated triphosphate analogue by viral polymerases but not host cell polymerases, thus reducing any side effects, and (3) once incorporated, further extension will be prevented by virtue of the 3’-blocking group, thereby inhibiting viral replication. These modified nucleotide analogues should be potent polymerase inhibitors and thus active against various viral diseases, including but not limited to the coronaviruses such as 2019-nCoV, and the strains causing SARS and MERS. Once incorporated, our newly designed nucleotide analogues containing 3’ blocking groups will permanently block further viral genome replication. This is in contrast to other nucleotide analogue-based viral inhibitors that have a free 3’ OH group, which have the possibility of allowing further polymerase extension, enabled by viral mutations. For the same reason, at high concentrations, nucleotide analogue-based viral inhibitors with free 3’ OH groups have the potential of being incorporated by host polymerases.
   </p>
   <p id="p-15">All RNA viruses are known to mutate at a high frequency, due to the low fidelity of the viral polymerase, resulting in the development of resistance to treatment. The promiscuous nature of the viral polymerase will allow incorporation of our newly designed nucleotide analogues as anti-viral agents.</p>
   <p id="p-16">Examples of nucleotide analogues designed by us to satisfy these criteria are provided in 
    <a id="xref-fig-6-1" class="xref-fig" href="#F6">Fig. 6</a>, and strategies for their synthesis in 
    <a id="xref-fig-7-1" class="xref-fig" href="#F7">Figs. 7</a>–
    <a id="xref-fig-9-1" class="xref-fig" href="#F9">9</a>; 
    <a id="xref-fig-10-1" class="xref-fig" href="#F10">Fig. 10</a> shows the activation of these prodrugs to form triphosphate analogues (same as for sofosbuvir in 
    <a id="xref-fig-3-2" class="xref-fig" href="#F3">Fig. 3</a>) that should be incorporated and inhibit the coronavirus and other RNA virus polymerases.
   </p>
   <div id="F6" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F6.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Example structures of nucleotide analogues as viral polymerase inhibitors with masked phosphate group, unmodified or modified at 2[[#x2019]] position, and blocking groups on the 3[[#x2019]] position." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;Example structures of nucleotide analogues as viral polymerase inhibitors with masked phosphate group, unmodified or modified at 2[[#x2019]] position, and blocking groups on the 3[[#x2019]] position.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 6:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F6.medium.gif" width="440" height="249"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 6:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F6.medium.gif" width="440" height="249"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F6.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 6:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F6.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 6:</span>
     <p id="p-17" class="first-child">Example structures of nucleotide analogues as viral polymerase inhibitors with masked phosphate group, unmodified or modified at 2’ position, and blocking groups on the 3’ position.</p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <div id="F7" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F7.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Synthesis of 3[[#x2019]]-O blocked nucleoside phosphoramidate analogues: [[#x3B2]]-D-2[[#x2019]]-deoxy-2[[#x2019]]-[[#x3B1]]-fluoro-2[[#x2019]]-[[#x3B2]]-C-methyl-3[[#x2019]]-O-methyladenosine nucleoside phosphoramidate as example." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;Synthesis of 3[[#x2019]]-O blocked nucleoside phosphoramidate analogues: [[#x3B2]]-D-2[[#x2019]]-deoxy-2[[#x2019]]-[[#x3B1]]-fluoro-2[[#x2019]]-[[#x3B2]]-C-methyl-3[[#x2019]]-O-methyladenosine nucleoside phosphoramidate as example.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 7:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F7.medium.gif" width="440" height="289"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 7:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F7.medium.gif" width="440" height="289"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F7.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 7:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F7.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 7:</span>
     <p id="p-18" class="first-child">Synthesis of 3’-O blocked nucleoside phosphoramidate analogues: β-D-2’-deoxy-2’-α-fluoro-2’-β-C-methyl-3’-O-methyladenosine nucleoside phosphoramidate as example.</p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <div id="F8" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F8.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Synthesis of 3[[#x2019]]-O blocked nucleoside phosphoramidate analogues: [[#x3B2]]-D-2[[#x2019]]-deoxy-2[[#x2019]]-[[#x3B1]]-fluoro-3[[#x2019]]-0-methylthiomethyluridine nucleoside phosphoramidate as example." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;div xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;;&gt;;Synthesis of 3[[#x2019]]-O blocked nucleoside phosphoramidate analogues: [[#x3B2]]-D-2[[#x2019]]-deoxy-2[[#x2019]]-[[#x3B1]]-fluoro-3[[#x2019]]-&lt;;em&gt;;0&lt;;/em&gt;;-methylthiomethyluridine nucleoside phosphoramidate as example.&lt;;/div&gt;;&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 8:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F8.medium.gif" width="440" height="221"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 8:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F8.medium.gif" width="440" height="221"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F8.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 8:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F8.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 8:</span>
     <p id="p-19" class="first-child">Synthesis of 3’-O blocked nucleoside phosphoramidate analogues: β-D-2’-deoxy-2’-α-fluoro-3’-
      <em>0</em>-methylthiomethyluridine nucleoside phosphoramidate as example.
     </p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <div id="F9" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F9.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Example synthesis of [[#x3B2]]-D-2[[#x2019]]-deoxy-2[[#x2019]]-[[#x3B1]]-fluoro-2[[#x2019]]-[[#x3B2]]-C-methyl-3[[#x2019]]-O-allyluridine nucleoside phosphoramidate." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;&lt;;div xmlns=&quot;;http://www.w3.org/1999/xhtml&quot;;&gt;;Example synthesis of [[#x3B2]]-D-2[[#x2019]]-deoxy-2[[#x2019]]-[[#x3B1]]-fluoro-2[[#x2019]]-[[#x3B2]]-C-methyl-3[[#x2019]]-&lt;;em&gt;;O&lt;;/em&gt;;-allyluridine nucleoside phosphoramidate.&lt;;/div&gt;;&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 9:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F9.medium.gif" width="440" height="87"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 9:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F9.medium.gif" width="440" height="87"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F9.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 9:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F9.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 9:</span>
     <p id="p-20" class="first-child">Example synthesis of β-D-2’-deoxy-2’-α-fluoro-2’-β-C-methyl-3’-
      <em>O</em>-allyluridine nucleoside phosphoramidate.
     </p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <div id="F10" class="fig pos-float type-figure odd">
    <div class="highwire-figure">
     <div class="fig-inline-img-wrapper">
      <div class="fig-inline-img">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F10.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Mode of activation of 3[[#x2019]]-blocked nucleotide prodrug precursors illustrated in Fig. 6 by cellular enzymes." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1933888578" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;Mode of activation of 3[[#x2019]]-blocked nucleotide prodrug precursors illustrated in Fig. 6 by cellular enzymes.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
        <span class="hw-responsive-img">
         <img class="highwire-fragment fragment-image lazyload" alt="Fig. 10:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F10.medium.gif" width="440" height="117"/>
         <noscript>
          <img class="highwire-fragment fragment-image" alt="Fig. 10:" src="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F10.medium.gif" width="440" height="117"/>
         </noscript>
        </span>
       </a>
      </div>
     </div>
     <ul class="highwire-figure-links inline">
      <li class="download-fig first">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F10.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 10:" data-icon-position="" data-hide-link-title="0">Download figure</a>
      </li>
      <li class="new-tab last">
       <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574/F10.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
      </li>
     </ul>
    </div>
    <div class="fig-caption">
     <span class="fig-label">Fig. 10:</span>
     <p id="p-21" class="first-child">Mode of activation of 3’-blocked nucleotide prodrug precursors illustrated in 
      <a id="xref-fig-6-2" class="xref-fig" href="#F6">Fig. 6</a> by cellular enzymes.
     </p>
     <div class="sb-div caption-clear"/>
    </div>
   </div>
   <p id="p-22">Synthesis of 3’-
    <em>O</em>-blocked nucleoside phosphoramidate prodrugs can be carried out starting from 2’-modified nucleosides (
    <a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">Ross et al 2011</a>). First, both the 5’-OH and the exocyclic amino group of the base will be protected. Then the 3’-OH will be derivatized with a variety of blocking groups, including methyl, ethyl, propyl, allyl, propargyl, methoxymethyl, methylthiomethyl, azidomethyl, etc., such as those listed in 
    <a id="xref-fig-6-3" class="xref-fig" href="#F6">Fig. 6</a>, following established methods (
    <a id="xref-ref-3-2" class="xref-bibr" href="#ref-3">Ju et al 2006</a>, 
    <a id="xref-ref-2-2" class="xref-bibr" href="#ref-2">Guo et al 2008</a>). After deprotection, the free 5’-OH is derivatized to afford the corresponding phosphoramidates by treatment with freshly prepared chlorophosphoramidate reagent in the presence of N-methyl imidazole (
    <a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">Sofia et al 2010</a>). 
    <a id="xref-fig-7-2" class="xref-fig" href="#F7">Fig. 7</a> and 
    <a id="xref-fig-8-1" class="xref-fig" href="#F8">Fig. 8</a> show example synthetic routes for the 3’-methoxy and 3’-O-methylthiomethyl nucleoside phosphoramidate analogs, respectively. Alternatively, starting from a 2’-modified nucleoside, the 5’-OH can be derivatized first to give 5’-phosphoramidate nucleotides, followed by 3’-OH derivatization to afford 3’-O blocked nucleoside phosphoramidate analogues. 
    <a id="xref-fig-9-2" class="xref-fig" href="#F9">Fig. 9</a> shows an example synthetic route for 3’-allyl nucleoside phosphoramidate analogues.
   </p>
   <div class="section ack" id="ack-1">
    <h2 class="">ACKNOWLEDGMENTS</h2>
    <p id="p-23">This research is supported by Columbia University, which has filed a patent application on the work described in this manuscript.</p>
   </div>
   <div class="section ref-list" id="ref-list-1">
    <h2 class="">References</h2>
    <ol class="cit-list ref-use-labels">
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference in text" id="ref-1">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.30.927574v1.1">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Alanazi</span>
          <span class="cit-name-given-names">AS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">James</span>
          <span class="cit-name-given-names">E</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Mehellou</span>
          <span class="cit-name-given-names">Y</span>
         </span> (
         <span class="cit-pub-date">2019</span>) 
         <span class="cit-article-title">The ProTide prodrug technology: where next?</span>
         <abbr class="cit-jnl-abbrev">ACS Med Chem Lett</abbr>
         <span class="cit-vol">10</span>:
         <span class="cit-fpage">2</span>–
         <span class="cit-lpage">5</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DACS%2BMed%2BChem%2BLett%26rft.volume%253D10%26rft.spage%253D2%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference in text" id="ref-2">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.30.927574v1.2" data-doi="10.1073/pnas.0804023105">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Guo</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Xu</span>
          <span class="cit-name-given-names">N</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>
          <span class="cit-name-given-names">Z</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wu</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>
          <span class="cit-name-given-names">DH</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Sano Marma</span>
          <span class="cit-name-given-names">M</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Meng</span>
          <span class="cit-name-given-names">Q</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Cao</span>
          <span class="cit-name-given-names">H</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>
          <span class="cit-name-given-names">X</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shi</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Yu</span>
          <span class="cit-name-given-names">L</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kalachikov</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Russo</span>
          <span class="cit-name-given-names">JJ</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Turro</span>
          <span class="cit-name-given-names">NJ</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Ju</span>
          <span class="cit-name-given-names">J</span>
         </span> (
         <span class="cit-pub-date">2008</span>) 
         <span class="cit-article-title">Four-color DNA sequencing with 3’-O-modified nucleotide reversible terminators and chemically cleavable fluorescent dideoxynucleotides</span>. 
         <abbr class="cit-jnl-abbrev">Proc Natl Acad Sci USA</abbr>
         <span class="cit-vol">105</span>:
         <span class="cit-fpage">9145</span>–
         <span class="cit-lpage">9150</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DProc%2BNatl%2BAcad%2BSci%2BUSA%26rft_id%253Dinfo%253Adoi%252F10.1073%252Fpnas.0804023105%26rft_id%253Dinfo%253Apmid%252F18591653%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMToiMTA1LzI3LzkxNDUiO3M6NDoiYXRvbSI7czo0ODoiL2Jpb3J4aXYvZWFybHkvMjAyMC8wMS8zMS8yMDIwLjAxLjMwLjkyNzU3NC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference in text" id="ref-3">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.30.927574v1.3" data-doi="10.1073/pnas.0609513103">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Ju</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kim</span>
          <span class="cit-name-given-names">DH</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bi</span>
          <span class="cit-name-given-names">L</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Meng</span>
          <span class="cit-name-given-names">Q</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bai</span>
          <span class="cit-name-given-names">X</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>
          <span class="cit-name-given-names">Z</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>
          <span class="cit-name-given-names">X</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Marma</span>
          <span class="cit-name-given-names">MS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shi</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wu</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Edwards</span>
          <span class="cit-name-given-names">JR</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Romu</span>
          <span class="cit-name-given-names">A</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Turro</span>
          <span class="cit-name-given-names">NJ</span>
         </span> (
         <span class="cit-pub-date">2006</span>) 
         <span class="cit-article-title">Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators</span>. 
         <abbr class="cit-jnl-abbrev">Proc Natl Acad Sci USA</abbr>
         <span class="cit-vol">103</span>:
         <span class="cit-fpage">19635</span>–
         <span class="cit-lpage">19640</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DProc%2BNatl%2BAcad%2BSci%2BUSA%26rft_id%253Dinfo%253Adoi%252F10.1073%252Fpnas.0609513103%26rft_id%253Dinfo%253Apmid%252F17170132%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTAzLzUyLzE5NjM1IjtzOjQ6ImF0b20iO3M6NDg6Ii9iaW9yeGl2L2Vhcmx5LzIwMjAvMDEvMzEvMjAyMC4wMS4zMC45Mjc1NzQuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference in text" id="ref-4">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.30.927574v1.4">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Ju</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>
          <span class="cit-name-given-names">Z</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Edwards</span>
          <span class="cit-name-given-names">JR</span>
         </span> and 
         <span class="cit-auth">
          <span class="cit-name-surname">Itagaki</span>
          <span class="cit-name-given-names">Y</span>
         </span> (
         <span class="cit-pub-date">2003</span>) 
         <span class="cit-chapter-title">Massive Parallel Method for Decoding DNA and RNA</span>. 
         <abbr class="cit-jnl-abbrev">United States Patent 6,664,079</abbr>.
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference in text" id="ref-5">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.30.927574v1.5" data-doi="10.1021/jo201492m">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Ross</span>
          <span class="cit-name-given-names">BS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Reddy</span>
          <span class="cit-name-given-names">PG</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>
          <span class="cit-name-given-names">H-R</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Rachakonda</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Sofia</span>
          <span class="cit-name-given-names">MJ</span>
         </span> (
         <span class="cit-pub-date">2011</span>) 
         <span class="cit-article-title">Synthesis of diastereomerically pure nucleotide phosphoramidates</span>. 
         <abbr class="cit-jnl-abbrev">J Org Chem</abbr>
         <span class="cit-vol">76</span>:
         <span class="cit-fpage">8311</span>–
         <span class="cit-lpage">8319</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DThe%2BJournal%2Bof%2Borganic%2Bchemistry%26rft.stitle%253DJ%2BOrg%2BChem%26rft.aulast%253DRoss%26rft.auinit1%253DB.%2BS.%26rft.volume%253D76%26rft.issue%253D20%26rft.spage%253D8311%26rft.epage%253D8319%26rft.atitle%253DSynthesis%2Bof%2Bdiastereomerically%2Bpure%2Bnucleotide%2Bphosphoramidates.%26rft_id%253Dinfo%253Adoi%252F10.1021%252Fjo201492m%26rft_id%253Dinfo%253Apmid%252F21916475%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1021/jo201492m&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=21916475&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F31%2F2020.01.30.927574.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference in text" id="ref-6">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.30.927574v1.6" data-doi="10.1021/jm100863x">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Sofia</span>
          <span class="cit-name-given-names">MJ</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bao</span>
          <span class="cit-name-given-names">D</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Chang</span>
          <span class="cit-name-given-names">W</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Du</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Nagarathnam</span>
          <span class="cit-name-given-names">D</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Rachakonda</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Reddy</span>
          <span class="cit-name-given-names">PG</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Ross</span>
          <span class="cit-name-given-names">BS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wang</span>
          <span class="cit-name-given-names">P</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>
          <span class="cit-name-given-names">H-R</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bansal</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Espiritu</span>
          <span class="cit-name-given-names">C</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Keilman</span>
          <span class="cit-name-given-names">M</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Lam</span>
          <span class="cit-name-given-names">AM</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Micolochick Steuer</span>
          <span class="cit-name-given-names">HM</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Niu</span>
          <span class="cit-name-given-names">C</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Otto</span>
          <span class="cit-name-given-names">MJ</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Furman</span>
          <span class="cit-name-given-names">PA</span>
         </span> (
         <span class="cit-pub-date">2010</span>) 
         <span class="cit-article-title">Discovery of a β-D-2’-Deoxy-2’-α-fluoro-2’-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span>. 
         <abbr class="cit-jnl-abbrev">J Med Chem</abbr>
         <span class="cit-vol">53</span>:
         <span class="cit-fpage">7202</span>–
         <span class="cit-lpage">7218</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bmedicinal%2Bchemistry%26rft.stitle%253DJ%2BMed%2BChem%26rft.aulast%253DSofia%26rft.auinit1%253DM.%2BJ.%26rft.volume%253D53%26rft.issue%253D19%26rft.spage%253D7202%26rft.epage%253D7218%26rft.atitle%253DDiscovery%2Bof%2Ba%2B%25CE%25B2-d-2%2527-deoxy-2%2527-%25CE%25B1-fluoro-2%2527-%25CE%25B2-C-methyluridine%2Bnucleotide%2Bprodrug%2B%2528PSI-7977%2529%2Bfor%2Bthe%2Btreatment%2Bof%2Bhepatitis%2BC%2Bvirus.%26rft_id%253Dinfo%253Adoi%252F10.1021%252Fjm100863x%26rft_id%253Dinfo%253Apmid%252F20845908%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1021/jm100863x&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=20845908&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F31%2F2020.01.30.927574.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference in text" id="ref-7">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.30.927574v1.7" data-doi="10.1038/nature13027">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Warren</span>
          <span class="cit-name-given-names">TK</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wells</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Panchal</span>
          <span class="cit-name-given-names">RG</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Stuthman</span>
          <span class="cit-name-given-names">KS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Garza</span>
          <span class="cit-name-given-names">NL</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Van Tongeren</span>
          <span class="cit-name-given-names">SA</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Dong</span>
          <span class="cit-name-given-names">L</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Retterer</span>
          <span class="cit-name-given-names">CJ</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Eaton</span>
          <span class="cit-name-given-names">BP</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Pegoraro</span>
          <span class="cit-name-given-names">G</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Honnold</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bantia</span>
          <span class="cit-name-given-names">S</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kotian</span>
          <span class="cit-name-given-names">P</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Chen</span>
          <span class="cit-name-given-names">X</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Taubenheim</span>
          <span class="cit-name-given-names">BR</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Welch</span>
          <span class="cit-name-given-names">LS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Minning</span>
          <span class="cit-name-given-names">DM</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Babu</span>
          <span class="cit-name-given-names">YS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Sheridan</span>
          <span class="cit-name-given-names">WP</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Bavari</span>
          <span class="cit-name-given-names">S</span>
         </span> (
         <span class="cit-pub-date">2014</span>) 
         <span class="cit-article-title">Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430</span>. 
         <abbr class="cit-jnl-abbrev">Nature</abbr>
         <span class="cit-vol">508</span>:
         <span class="cit-fpage">402</span>–
         <span class="cit-lpage">405</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNature%26rft.volume%253D508%26rft.spage%253D402%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnature13027%26rft_id%253Dinfo%253Apmid%252F24590073%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1038/nature13027&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=24590073&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F31%2F2020.01.30.927574.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000334403000053&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference in text" id="ref-8">↵</a>
      <div class="cit ref-cit ref-web" id="cit-2020.01.30.927574v1.8" data-doi="10.1056/NEJMoa2001017">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Zhu</span>
          <span class="cit-name-given-names">N</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>
          <span class="cit-name-given-names">D</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wang</span>
          <span class="cit-name-given-names">W</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>
          <span class="cit-name-given-names">X</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Yang</span>
          <span class="cit-name-given-names">B</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Song</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhao</span>
          <span class="cit-name-given-names">X</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Huang</span>
          <span class="cit-name-given-names">B</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shi</span>
          <span class="cit-name-given-names">W</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Lu</span>
          <span class="cit-name-given-names">R</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Niu</span>
          <span class="cit-name-given-names">P</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhan</span>
          <span class="cit-name-given-names">F</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Ma</span>
          <span class="cit-name-given-names">X</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wang</span>
          <span class="cit-name-given-names">D</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Xu</span>
          <span class="cit-name-given-names">W</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wu</span>
          <span class="cit-name-given-names">G</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Gao</span>
          <span class="cit-name-given-names">GF</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Tan</span>
          <span class="cit-name-given-names">W</span>
         </span>, 
         <span class="cit-auth cit-collab">for the China Novel Coronavirus Investigating and Research Team</span> (
         <span class="cit-pub-date">2020</span>) 
         <span class="cit-article-title">A novel coronavirus from patients with pneumonia in China, 2019</span>. 
         <span class="cit-source">N Eng J Med</span>.
         <span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span>
         <span class="cit-pub-id-scheme">DOI: </span>
         <span class="cit-pub-id cit-pub-id-doi">10.1056/NEJMoa2001017</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DN%2BEng%2BJ%2BMed%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2001017%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1056/NEJMoa2001017&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label ref-label-empty"/>
      <a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference in text" id="ref-9">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.30.927574v1.9">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Zumla</span>
          <span class="cit-name-given-names">A</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Chan</span>
          <span class="cit-name-given-names">JFW</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Azhar</span>
          <span class="cit-name-given-names">EI</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Hui</span>
          <span class="cit-name-given-names">DSC</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Yuen</span>
          <span class="cit-name-given-names">K-Y</span>
         </span> (
         <span class="cit-pub-date">2016</span>) 
         <span class="cit-article-title">Coronaviruses – drug discovery and therapeutic options</span>. 
         <abbr class="cit-jnl-abbrev">Nat Rev J Drug Discovery</abbr>
         <span class="cit-vol">15</span>:
         <span class="cit-fpage">327</span>–
         <span class="cit-lpage">347</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNat%2BRev%2BJ%2BDrug%2BDiscovery%26rft.volume%253D15%26rft.spage%253D327%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
       </div>
      </div>
     </li>
    </ol>
   </div>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
